Alaa Halawa

Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.

Metsera is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission to advance the next generation of medicines for obesity and cardiometabolic diseases. Learn more here: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera Metsera social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer for updates: https://www.linkedin.com/company/pfizer/

UpStream is the fastest-growing primary healthcare solution provider in the US. We underwrite and support the delivery of value-based care for older patients and people living with chronic conditions. By working in partnership with healthcare practices and clinics we offer a comprehensive risk-free solution for physicians that finances, delivers and sustains better outcomes for everyone. UpStream’s proven risk-free solution for physicians is called GAP-QTM (Guaranteed Advanced Payments for Quality). It combines global risk-management services with embedded professional services — all facilitated and integrated by our state of the art digital platform. GAP-QTM benefits physicians and practices through increased income and professional satisfaction. Patients benefit through reduced hospital admissions, reduced copayments, increased benefits and satisfaction, and improved health. Their informal caregivers also benefit from the significantly reduced burden and stress.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease. Based on these insights, we are discovering new medicines to treat cancer and inflammatory diseases. Interline is headquartered in Brisbane, CA.

Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora is relentless in its commitment to discovering, developing and commercializing novel therapies for the 1.5 billion people living with brain diseases.

Developing next generation technologies for precision medicine and drug discovery.

Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

Effective 11/09/23, EQRx., Inc. is now a wholly-owned subsidiary of Revolution Medicines (https://www.revmed.com/)

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Science 37 is a clinical research site that delivers trials directly to patients homes. We accelerate research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

We’re moving! Stay connected with the Invitae Ciitizen community by following us on Linked, @Invitae

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. At Lyell, our goal is to change that. We are a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for solid tumors based on our innovative technologies. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to defeat solid tumors, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our missions urgency.

ThruAi is an AI R&D company whose mission is accelerating the diffusion of Generative AI into highly regulated industries. Our first product is an AI Model & Workflow studio that enables professional, teams and companies to privately and easily interact with multiple foundational LLM models while developing their own personalized knowledge Graph.

Salma Health is a comprehensive brain health clinic combining advanced diagnostics, personalized treatment and continuous care under one roof. Our team specializes in mental health, cognitive health and neurological recovery, offering evidence-based therapies for conditions like depression, anxiety, PTSD and brain injury. From your first evaluation to ongoing care, we guide every step of your journey with clarity, compassion and science-driven support.

Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.

Metsera is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission to advance the next generation of medicines for obesity and cardiometabolic diseases. Learn more here: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera Metsera social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer for updates: https://www.linkedin.com/company/pfizer/

UpStream is the fastest-growing primary healthcare solution provider in the US. We underwrite and support the delivery of value-based care for older patients and people living with chronic conditions. By working in partnership with healthcare practices and clinics we offer a comprehensive risk-free solution for physicians that finances, delivers and sustains better outcomes for everyone. UpStream’s proven risk-free solution for physicians is called GAP-QTM (Guaranteed Advanced Payments for Quality). It combines global risk-management services with embedded professional services — all facilitated and integrated by our state of the art digital platform. GAP-QTM benefits physicians and practices through increased income and professional satisfaction. Patients benefit through reduced hospital admissions, reduced copayments, increased benefits and satisfaction, and improved health. Their informal caregivers also benefit from the significantly reduced burden and stress.